ESR2 and breast cancer: Related to these anti-proliferative effects, it has also been reported that ERβ-positive tumours may respond more favourably to tamoxifen, and ERβ agonist treatment of ERα-positive breast cancer cell lines appear to enhance their sensitivity to tamoxifen [63, 64].